This retrospective single-center study compared the incidence, spectrum and effect of infections in 1045 consecutive allogeneic (allo) and autologous (auto) hematopoietic SCT (HSCT) performed between 1995 and 2006 in the inpatient (IP) or outpatient (OP) setting. We analyzed 374 allo-HSCT (196 IP and 178 OP) and 671 auto-HSCT (163 IP and 508 OP). The incidence of infection was lower both in auto-OP (25% OP vs 33% IP, P ¼ 0.042) and allo-OP cohorts (42.7% OP vs 55.6% IP, P ¼ 0.012). The mean number of infections per transplant was lower in both auto-OP (0.39 OP vs 0.57 IP, P ¼ 0.05) and in allo-OP cohorts (0.78 OP vs 1.09 IP, P ¼ 0.018). The 100-day non-relapse mortality (NRM) for OP auto-HSCT was 4.72% and for IP 3.95% (P ¼ 0.68). The 100-day NRM for OP allo-HSCT was lower at 14.1% than it was for IP at 22.6% (P ¼ 0.041). Time to onset of first infection and spectrum of infections was similar in all groups. We conclude that performing allo-and auto-HSCT in the OP setting results in short-term outcomes, including infections complications that are comparable to the standard IP setting.
Introduction
Minimizing infectious complications through the provision of protective isolation in an inpatient (IP) setting for hematopoietic SCT (HSCT) has been considered the standard of care. 1 Peters et al. 2 were the first to develop a structured outpatient (OP) autologous program for stage 2-4 breast cancer patients receiving a high-dose chemotherapy regimen, which did not induce significant toxicity. There are currently three variations of the model: early discharge, delayed admission and a comprehensive or total OP model. 3, 4 A growing number of studies showing the feasibility, safety and cost reduction of OP auto-HSCT in patients with hematological malignancies have led to an increased acceptance of this approach. [5] [6] [7] [8] However, extension of this model into the allogeneic (allo)-HSCT transplant population has not occurred. An early publication by Russell et al. 9 described 50 consecutive patients receiving an allo-HSCT, nursed in a single room that included a subset of patients who were allowed to go home during their neutropenic phase. In this study, mortality data compared favorably with those institutions enforcing strict isolation procedures. A subsequent publication by Russell et al. (2000) 10 reported the results of 288 consecutive adult and pediatric allo-HSCT recipients transplanted without protective isolation and concluded that infectious and mortality outcomes were similar to those reported to the International Bone Marrow Transplant Registry. Recently van Tiel et al.
11 published a review of six studies describing home care vs hospital care of patients with hematological malignancies after HSCT and suggested no benefit for protective isolation environments. In a unique approach Svahn et al. (2002) , 12 described a model in which treatment at home was provided for allo-HSCT during the pancytopenic phase. This study found home care advantageous compared with hospital care. Use of non-myeloablative conditioning regimens has also been an impetus for considering moving allogeneic recipients to the OP setting for their transplant procedure. 13 In 1995, after having initiated and evaluated a successful pilot OP program in autologous transplant recipients, The Ottawa Hospital Blood and Marrow Transplant Program created a comprehensive OP transplant model for all transplant types: autologous, allogeneic related and unrelated. This study describes and compares the rate, type and spectrum of infections and overall transplant outcomes, including mortality rates between patients where the intention to treat was in the OP setting to those patients where the intention to treat was in the IP program.
Patients and methods

Patients
We performed a retrospective cohort study of 374 allogeneic (220 related, 20 haploidentical and 134 unrelated) transplant recipients and 671 autologous transplant patients consecutively transplanted between January 1995 and July 2006. Only autologous transplant recipients who were transferred day þ 1 back to their referring institutions were not included in the analysis.
14 All patients signed a research ethics board approved informed consent to participate in the OP program. Table 1 describes the demographic data.
Methods
The HSCT program at The Ottawa Hospital has a concurrent data entry system in which data are captured and entered into a Microsoft Access database (Microsoft, Redmond, WA, USA). Policies and procedures have been developed and implemented for auditing data entry. This study captures the initial transplant period from start of conditioning regimen until discharge. All confirmed infections were captured. Patients were analyzed according to where they were the day the product was infused (day 0). All patients consented to anonymous data collection and analysis.
Eligibility for participation in the outpatient program Since 1995, all patients have been considered eligible for participation in the OP program. Although they were free to not participate, when they did not, the reason was captured. The criteria for acceptance into the OP program were as follows: availability of a caregiver(s) 24 h/day, accommodation within 1 h of the hospital, ability to commute daily and the ability to maintain self-care activities. Once patients consented to participate, the attending physician had to agree that the patient was clinically stable to participate in the OP program.
Outpatient setting
The OP unit was developed within the IP HSCT unit. Originally two IP beds were converted to day hospital OP beds operating 13 h/day, 365 days/year. In 1997, because of volume demands, this expanded to become a four bed unit. Patients were considered 'admitted' to the OP unit to facilitate continuity with one continuous hospital chart and uninterrupted medication order entry and delivery mechanisms that duplicated the IP system. All prescribed medications were provided free to the OP cohort. After hours, physician coverage was provided by the HSCT attending physician on call.
Caregiver/patient responsibilities Patients were observed daily in the OP unit. No external home care nursing services were provided. Patients were instructed not to drive themselves so caregivers assumed responsibility for transportation. Patients and caregivers were given daily written instruction for the administration of medications. In addition, they were asked to monitor temperature and record intake and output. The goal of the OP program was to streamline care not to train caregivers and patients to deliver complex care at home.
No specific infectious risk prevention strategies were given to patients and caregivers. Basic hand washing was reviewed, crowd minimization was encouraged and chicken-pox awareness highlighted; however, patients were not expected to isolate themselves from their own children. Pets were allowed to remain in the home as well. No dietary restrictions other than adequate preparation and storage to prevent bacteria contamination were suggested.
Conditioning regimens
Standard chemotherapy regimens were used. TBI was used in single or fractionated doses. 15, 16 Only 19 allogeneic transplant patients (0.05%) received reduced intensity conditioning regimens. 
Supportive care
All patients had an indwelling central venous catheter placed before commencing conditioning regimens. Double lumen Hickman catheters (Bard Access Systems, Salt Lake City, UT, USA) were replaced by peripherally inserted central catheters from 1999 onward. 17 Standard antiemetic regimens were used.
For mild-to-moderate pain, patients received oral codeine or morphine. For moderate-to-severe pain, transdermal fentanyl was used with as needed morphine for breakthrough pain. Patients could not be prescribed more than two narcotics for pain control. If additional analgesia was needed patients were admitted. Keratinocyte growth factor was not administered to any patient.
Other than trimethoprin/sulfamethoxazole for Pneumocystis carinii, no antibacterial prophylaxis was administered. Oral acyclovir 400 mg twice daily from day þ 1 until neutrophil engraftment was administered to all patients. Allogeneic transplant recipients received oral fluconazole 100 mg daily for the same time period.
Autologous transplant recipients received G-CSF 300 mg daily for patients weighing o70 kg and 480 mg for patients weighing 470 kg was administered day þ 1. This practice changed in 1998 when randomized data from an internal study indicated no difference between G-CSF day 1 vs day 7 after auto-HSCT. 18 G-CSF was continued until the ANC was 40.5 Â 10 9 /l for 2 consecutive days. G-CSF was not routinely administered to allogeneic recipients.
Blood cultures were drawn from central catheters the first time the patient had a temperature 438.5 1C. Blood cultures continued to be drawn once daily from the central line if fever persisted or at the time of a new febrile episode. Patients with uncomplicated febrile neutropenia received immediate monotherapy treatment with i.v. ceftriaxone 1 g daily. 19 If the only clinical finding was fever, patients remained in the OP program. If patients were transferred to the IP program, antibiotic coverage was changed to either ceftazidime or piperacillin-tazobactam. Antibiotic coverage was adjusted if blood cultures were positive. Once patients commenced i.v. antibiotics they were continued until recovery of neutrophil count. Patients had daily complete blood counts and electrolyte monitoring. Liver function tests were performed twice weekly. All blood products were irradiated. Only allogeneic unrelated recipients received CMV sero-negative products. RBCs were given if the hemoglobin level was o90 g/l. Plts were routinely administered in afebrile patients when the plt count was o20 Â 10 9 /l or 30 Â 10 9 /l if febrile. Graft-vs-host disease prophylaxis was standard oral CYA or Tacrolimus twice daily followed by short course MTX. Folinic acid was not routinely administered. Enoxaparin 20 mg subcutaneously daily was administered for veno-occlusive disease prophylaxis in allogeneic recipients. Low dose 2.5 mg/kg of rabbit anti-thymocyte globulin (Thymoglobulin, Genzyme Corporation, Cambridge, MA, USA) was given to all unrelated donor transplant recipients as GVHD prophylaxis from June 1997 onward.
Criteria for admission to the in-patient unit Specific criteria for admission were developed including uncontrolled emesis, nausea, diarrhea, pain, hemodynamic instability, deterioration of patient condition, requirement of greater than twice daily i.v. therapy and/or loss of caregiver support. Patients could at any time request and receive admission to the IP unit.
Statistical analysis
Baseline characteristics of patients enrolled were assessed through computation of measures of central tendency and dispersion for all relevant risk factors. All analyses of baseline and outcome measures were stratified by allogeneic vs autologous transplant type, findings are presented separately for these groups. To compare the per-patient rate of infection between IP and OP, we compared mean and median numbers of infection, both overall and by graft source, using t-tests and Wilcoxon rank-sum tests. Time to first infection after BMT was also compared in the IP and OP groups using both the log-rank test (with examination of associated Kaplan-Meier curves) and Cox proportional hazards modeling. The first instance of antibiotic administration was used as the time of first infection for the purposes of analysis, and only transplants that developed infection were included.
Non-relapse mortality (NRM) rates in the IP and OP programs at 30 and 100 days were calculated for both graft source groups, as well as overall, and compared using w 2 /Fisher's exact testing as necessary. Logistic regression was also used to calculate adjusted odds of mortality in both groups after adjustment for the effects for age, gender and diagnosis. The cause of death in the IP vs OP programs was studied to see if one group showed more infectionrelated deaths and the number of fatal and non-fatal infection between the two groups was also compared.
Results
We analyzed the outcomes of 374 allogeneic (196 IP and 178 OP) and 671 auto-HSCT (163 IP and 508 OP). There were no statistical differences in the groups for age, gender, disease and stem cell source or cell count of the graft (Table 1) .
In all, 47% of the allogeneic recipients were in the OP program on day 0. The length of stay for the OP group was 5 days less than the IP cohort. For allogeneic recipients who were IP on day 0, the median number of days spent in the OP program was 7 compared with 20 for the patients who were in the OP program at day 0.
Overall, 76% of autologous recipients were in the OP program on day 0. The median total length of stay for this group of patients was 3 days less (21 vs 24 days) than for the IP group. For autologous recipients who were IP on day 0, the median number of days spent in the OP program was 2 compared with 14 for the patients who were in the OP program at day 0 (Table 2) . Table 3 provides a summary of reasons for IP location on day 0. Reasons for admission to the IP unit for the autologous group varied compared with the allogeneic group. Of the 24% of autologous recipients (n ¼ 163) who were admitted to the IP program on day 0, 30% (n ¼ 50) of patients were admitted because they did not meet the caregiver/accommodation criteria. In the allogeneic cohort, where 53% (n ¼ 196) were admitted to the IP program on day 0, 19% (n ¼ 48) were admitted because they were felt to be clinically unstable. Examples given for clinical instability included disease progression (n ¼ 15), existing infections (n ¼ 12), renal dysfunction (n ¼ 5), pain (n ¼ 4), tumor lysis syndrome (n ¼ 2), deep vein thrombosis (n ¼ 2) and other (n ¼ 8). Overall 23% (n ¼ 37) of autologous recipients were admitted because of clinical instability. Examples given for clinical instability included progressive disease (n ¼ 7), existing infections (n ¼ 5), cardiac co-morbidity (n ¼ 4), tumor lysis syndrome (n ¼ 3), pleural effusions (n ¼ 3) renal dysfunction (n ¼ 3), uncontrolled blood sugar (n ¼ 3), pain (n ¼ 2), conditioning regimen related toxicity (n ¼ 2) and other (n ¼ 5). The second most common reason for allogeneic recipients to be admitted was lack of caregiver/ transportation. This accounted for 17% of the admissions.
Reasons for in-patient admission
Eleven percent (n ¼ 21) of unrelated transplant recipients were transferred to the IP unit on day 0 for completion or initiation of the unrelated stem cell product. All but one recipient returned to the OP setting the following day. Six percent (n ¼ 11) of allogeneic unrelated recipients were admitted because of a systemic reaction to the Thymoglobulin infusion.
Safety
One 68-year-old male with multiple myeloma receiving an autologous transplant died during sleep at home on day þ 7. He was neutropenic, without fever, and not on antibiotics and there were no known co-morbidities. No autopsy was performed.
Thirteen patients (2.0%) went directly from the OP program to the intensive care unit (ICU): 3 allogeneic recipients and 10 autologous recipients. All three allogeneic recipients were admitted to the ICU because of sepsis; one aspergillosis, one clostridium difficile and one Pseudomonas. Two patients were young males with refractory leukemia while the other was a 49-year-old male in first CR AML. All patients subsequently died in the ICU on day þ 1, day þ 44 and day þ 15, respectively.
For the autologous recipients, 10 (2.0%) went directly from the OP program to the ICU. Three patients with Gram neg sepsis, one candida sepsis, two blood culture negative septic shock, one mucositis, one seizure, one hemolysis after cryopreserved BM infusion and one patient with engraftment syndrome. The patient with fungal sepsis died in the ICU, while all other patients were subsequently discharged from ICU with full recovery.
Patient/caregiver acceptability
In the early phases of development of the OP program patient and caregiver questionnaires were distributed after discharge. A response rate of 73% (n ¼ 35) was achieved. Overall, 70% (n ¼ 25) of patients rated their overall impression of the program as 'very good to excellent' whereas 13% (n ¼ 5) found the experience unsatisfactory. Over 90% (n ¼ 32) responded that they felt they could get in touch with a physician or nurse quickly if required. They were also confident that they would have been transferred to the IP setting if they could not remain in the OP program.
Frequency and type of infections
The types and relative proportion of infections documented in the different cohorts are illustrated in Figure 1 . There were no statistically significant differences in the relative incidence of types of infections documented between the IP and OP cohorts.
The mean number of infections in the allo-IP cohort was 1.09 and 0.78 in the comparable OP cohort (P ¼ 0.018). In the auto-IP cohort the mean number of infections was 0.57 and 0.39 in the OP cohort (P ¼ 0.059). Overall the mean number of infections for the entire IP cohort (both autologous and allogeneic) (n ¼ 359) was 0.86 and for the OP cohort (n ¼ 686) was 0.49. This was statistically significant with a P-value of o0.0001. The cumulative proportion of IP allogeneic recipients with infections was (18, 27) 7 (2, 12) 14 (11, 17) Abbreviations: allo ¼ allogeneic; auto ¼ autologous; LOS ¼ length of stay. 55.6% compared with 42.7% for OP (P ¼ 0.0126) (Figure 2) . In the IP autologous group, 33% had infections compared with 25% in the OP group (P ¼ 0.042) (Figure 3 ). There were no differences in time to first infection in IP or OP cohorts (Figures 2 and 3 ).
Non-relapse mortality Autologous transplants. The 30-day NRM was not observed to be statistically different for the IP group from the OP group, and this finding also held true for 100-day mortality. Adjusted odds mortality after 30 days was 1.108 times higher for the IP than for OP and for mortality after 100 days the odds of IP was 0.936 times for OP.
Allogeneic transplants. The 30-day NRM rate was observed to be higher for the IP group as compared with the OP group. This finding persisted for 100-day mortality. The adjusted odds mortality after 30 days was 3.744 times higher for IP than for OP and for mortality after 100 days it was 2.113 times higher for IP than OP. When both autologous and allogeneic groups were combined the NRM rate was observed to be higher for the IP group at 30 days (P ¼ 0.0074) and 100 days (P ¼ 0005). Table 4 describes 30-and 100-day NRM rates.
Discussion
We describe an extensive experience of using an OP model of care delivery for over 1000 allogeneic and autologous transplants. Although infections represent an important cause of morbidity and mortality after HSCT, the kind of infection observed in the OP cohort is identical to that observed in the IP cohort ( Figure 1 ) suggesting that factors intrinsic to the patient are more important than extrinsic factors. Intrinsic factors contributing to infections include depth and duration of neutropenia, mucositis, enteritis and the presence of indwelling catheters. 20 What extrinsic factors contribute to infectious complications remains debatable but historically there have been strong recommendations from clinical experts to try and control these factors. The Centers for Disease Control, with input from the Infectious Disease Society of America and the American Society of Blood and Marrow Transplantation have published guidelines that contain more than 200 recommendations for infection control among HSCT recipients. 21 However, only seven are supported by Level 1 evidence. None of these relate to the use of patient isolation units, ventilation systems, construction or cleaning guidelines, skin or oral care or the prevention of catheter associated infections. The number one infection control recommendation is for simple hand washing a strategy that is easily taught to patients and family members. Although more recent publications have alluded to the potential detrimental effects of nosocomial infections in hospital settings when the OP program was established in 1995, there was strong support for the use of environmental infection control measures to minimize infections in HSCT recipients. [22] [23] [24] [25] The literature suggested the use of laminar air flow units, patient isolation units, prophylactic antibiotics, anti-microbial contamination and low-microbial diets improved survival among patients. Despite this trend, our OP program was established without the use of any of these environmental controls.
Timely initiation of appropriate antibiotic therapy was observed as an important risk factor to emphasize. The establishment of the OP program adjacent to the IP unit ensured that the health-care providers, physicians, nurses, reviewed 278 allogeneic and 455 autologous recipients transplanted at our institution between 1995 and 2003. They reported that 99.2% of all patients had febrile neutropenia with 57.4% having documented infections. This is a higher incidence of documented infection than reported in the literature. Publication by other investigators at that time supported the practice of culturing blood samples obtained from a central venous catheter was adequate. 27, 28 The time to first infection and initiation of i.v. antibiotics was similar in the OP and IP cohorts (Figures 2 and 3) , suggesting that there was no delay in the diagnosis and treatment of infection.
Ceftriaxone is a third-generation cephalosporin with a long elimination half-life, effective against a broad range of Gram-positive and Gram-negative bacteria. 29 Despite the low activity of once daily i.v. Ceftriaxone against some resistant gram negative pathogens such as Pseudomonas aeruginosa, 30 the transplant physicians in conjunction with infectious disease specialists and our clinical pharmacist agreed to use it as monotherapy only in the OP group. To date we have not observed any drug-resistant organisms. Comparable length of stay data ( Table 2 ) and rates of ICU admission between the IP and OP cohorts suggest that initiation of monotherapy OP antibiotics is timely and effective in this model. Antibiotic and fungal prophylaxis has resulted in the emergence of different species of infectives and has contributed to the development of resistant organisms. 19 Our decision to not use anti-microbial fluroquinalone prophylaxis may be a determinant. Another contributing factor may be our central venous access device insertion practice. All stem cell collections are performed using peripheral venous access so for many autologous patients indwelling central catheters are inserted for 3 weeks or less. 31 There are particular issues that need to be addressed by anyone interested in adopting our model in their HSCT program. In addition to developing and delivering medical care strategies suitable for administration in the OP venue, the continued success of this model at our institution is based on five additional factors: (1) integration of the OP program with the IP unit; (2) patient access to a highly experienced multi-disciplinary team 24 h/day for 365 days/ year; (3) availability of alternative accommodation and funds to support OP patient activities; (4) availability of reliable caregivers; and (5) lack of the development of drugresistant organisms. We have chosen not to transfer complex care to the OP setting but the complexity of delivering such a comprehensive program should not be minimized. We are confident that we have developed a safe, acceptable care delivery model that enhances the quality of life for patients' and their families while maximizing efficient use of IP beds and institutional fiscal resources. Table 4 30-and 100-day non-relapse mortality rates 
